Beam Therapeutics Inc (BEAM) Stock Analysis
Verdict: HOLD
Strong cash position and clinical momentum are countered by a high valuation premium and recent intellectual property setbacks.
Investment score: 64/100
Analysis as of
Is Beam Therapeutics Inc stock worth reviewing? AI model thesis
BEAM offers a high-conviction clinical platform but faces valuation headwinds and recent legal friction.
7-factor investment score
- Valuation: 45/100 (weight 20%)
- Financial Health: 85/100 (weight 15%)
- Technical Momentum: 60/100 (weight 15%)
- Earnings Quality: 78/100 (weight 15%)
- Insider Sentiment: 30/100 (weight 10%)
- Analyst Consensus: 82/100 (weight 10%)
- Risk-Adjusted Return: 55/100 (weight 15%)
Beam Therapeutics Inc opportunities and risks
What speaks for BEAM
- Clinical Validation of BEAM-101
What speaks against BEAM
- Intellectual Property Vulnerability
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| BEAM | n/a | 20.5x | n/a | -39.2% | -39.7% | -11.4% |
| IDYA | n/a | 15.6x | n/a | -8.7% | -62.2% | -2.5% |
| ARQT | n/a | 8.3x | 236.2x | 90.9% | -0.6% | 0.8% |
| VKTX | n/a | 0.0x | n/a | 0.0% | 0.0% | -7.5% |
| RARE | n/a | 5.0x | n/a | 83.6% | -91.0% | -14.6% |
| Peer median | n/a | 6.7x | n/a | 41.8% | -31.4% | -5.0% |
Frequently asked questions about Beam Therapeutics Inc (BEAM)
Is BEAM stock a good investment?
The cached TradeMates AI model rates Beam Therapeutics Inc as HOLD with an investment score of 64/100. BEAM offers a high-conviction clinical platform but faces valuation headwinds and recent legal friction. This is algorithmic model output, not personal investment advice.
Is BEAM stock a buy?
The TradeMates model verdict for BEAM is HOLD with an investment score of 64/100. Treat this as a model signal to review, not a personal buy recommendation.